Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Menopause & Women's Health

CoverageMenopause & Women's Health

Does menopausal hormone therapy prevent osteoporosis and fractures?

Can HRT prevent osteoporosis? Estrogen-based therapy reduces bone loss and fracture risk in postmenopausal women.

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·14 studies analyzed·2 core studies·Applies to: perimenopausal and early postmenopausal women

Bottom line

Estrogen-based therapy reduces bone loss and fracture risk in postmenopausal women, with benefit most established during early postmenopause. Guidelines support HRT for fracture prevention primarily when indicated for vasomotor symptoms or in high-risk women.[1–6]

Evidence confidence

Evidence Confidence

High
LimitedModerateHigh

Multiple high-quality studies directly address this question, with generally consistent findings.

Key uncertainty. Fracture benefit magnitude depends on baseline bone density, age, and concurrent osteoporosis therapy.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

hrt and osteoporosis prevention▼

WHI and later analyses show estrogen-based HRT reduces fractures. Use it for osteoporosis prevention when vasomotor symptoms or high fracture risk already justify treatment.

can hrt prevent osteoporosis▼

Yes — estrogen-based therapy can prevent osteoporosis-related bone loss and reduce fractures, with the strongest evidence in early postmenopause. It is not required for every postmenopausal woman.

does hormone replacement therapy help with osteoporosis▼

Hormone replacement therapy helps osteoporosis by slowing bone-mineral-density loss and lowering fracture rates. Guidelines treat this as a benefit of indicated HRT, not first-line osteoporosis drug therapy for all women.

osteoporosis hormone treatment▼

Osteoporosis hormone treatment in postmenopausal women is primarily estrogen-based therapy. Bone benefit is established; choose HRT when symptoms or high fracture risk justify it, alongside standard bone care.

hrt and osteoporosis▼

HRT and osteoporosis are linked: estrogen loss accelerates bone loss, and estrogen-based HRT reduces fracture risk. Benefit size depends on age, baseline bone density, and concurrent osteoporosis therapy.

bioidentical hormone replacement therapy and osteoporosis▼

Approved estradiol — including bioidentical estradiol — has bone-density and fracture data. Custom-compounded bioidentical combinations lack equivalent fracture trials.

Bioidentical vs conventional HRT evidence

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 13 relevant studies.

Overall finding

6 studies address venous thromboembolism, with weighted findings showing mixed findings. 6 studies address breast cancer, with weighted findings showing mixed findings. 5 studies address vasomotor symptom associations, with weighted findings showing mixed findings. 5 studies address mortality, with weighted findings showing mixed findings. 6 randomized or systematic-review reports and 5 observational studies address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Mixed

Venous thromboembolism

moderate · 6 studies

6 studies address venous thromboembolism, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 12117397PMID 26544651PMID 35713694PMID 36749328PMID 30626577
Mixed

Breast cancer

moderate · 6 studies

6 studies address breast cancer, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 12117397PMID 32721007PMID 35713694PMID 23543779PMID 36749328
Mixed

Vasomotor symptom associations

moderate · 5 studies

5 studies address vasomotor symptom associations, with weighted findings showing mixed findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 41307293PMID 29322164PMID 26838086PMID 36749328PMID 34513605
Mixed

Mortality

moderate · 5 studies

5 studies address mortality, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 12117397PMID 32721007PMID 23543779PMID 30626577
Harm signal

Fractures

high · 2 studies

2 studies address fractures, with weighted findings showing harm. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 12117397
Harm signal

Long-term cognitive decline / dementia

moderate · 2 studies

2 studies address long-term cognitive decline / dementia, with weighted findings showing harm. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 34513605

Magnitude / clinical importance

Validated effect estimates in the analyzed set include RR 1.17; HR = 1.55; odds ratio 1.58. Statistical significance is not the same as clinical importance.

Where quantified, effects were often statistically detectable but small in absolute terms.

Agreement across studies

Most studies agree on vasomotor symptom associations (mixed findings), while venous thromboembolism findings are mixed findings and less consistent across domains.

Supports main conclusion: 5 · Neutral / mixed: 8 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • Long-term follow-up of women using hormone therapy suggests that the risk profiles vary between combined hormone therapy and oestrogen-only therapy.
  • Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women.
  • MHT has a complex pattern.
  • PURPOSE OF REVIEW: To review recent research regarding cognitive problems during perimenopause, including which menopause-related symptoms, demographic variables, stress exposures, and neural biomark…

Risks & harms

5 studies report safety-relevant findings. Design mix: Randomized controlled trial, Systematic review / meta-analysis, Study design not clearly classified, Narrative review. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included perimenopausal and early postmenopausal women.

What remains uncertain

  • Fracture benefit magnitude depends on baseline bone density, age, and concurrent osteoporosis therapy.
  • Fracture benefit magnitude depends on baseline bone density, age, and concurrent osteoporosis therapy.
  • Surrogate improvement does not prove a hard clinical outcome.
  • Typical subjective cognitive complaints are not established as equivalent to dementia.

Clinical takeaway

Use estrogen-based therapy for fracture prevention primarily when vasomotor symptoms or other indications already justify treatment, or when osteoporosis risk is high. Bone benefit is real but does not require HRT in every postmenopausal woman.

Mixed

Venous thromboembolism?

Mixed findings

moderate[41307293 · 12117397 · 26544651 · 35713694 · 36749328 · 30626577]

Mixed

Breast cancer?

Mixed findings

moderate[41307293 · 12117397 · 32721007 · 35713694 · 23543779 · 36749328]

Mixed

Vasomotor symptom associations?

Mixed findings

moderate[41307293 · 29322164 · 26838086 · 36749328 · 34513605]

Mixed

Mortality?

Mixed findings

moderate[41307293 · 12117397 · 32721007 · 23543779 · 30626577]

Harm signal

Fractures?

Harm

high[41307293 · 12117397]

Harm signal

Long-term cognitive decline / dementia?

Harm

moderate[41307293 · 34513605]

Unclear

Fertility / spermatogenesis?

Unclear findings

moderate[41307293]

Mixed

Mood-related cognitive symptoms?

Mixed findings

moderate[29322164]

6 randomized or systematic-review reports and 5 observational studies address treatment. Weighted treatment findings show mixed findings.

6 RCT / systematic review · 5 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

12 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Evidence beyond long follow-up windows and in certain subgroups remains less complete.

13 analyzed studies

Strongest evidence

The Cochrane database of systematic reviews2025

Landmark studyPMID 41307293

Long-term hormone therapy for perimenopausal and postmenopausal women.

Long-term follow-up of women using hormone therapy suggests that the risk profiles vary between combined hormone therapy and oestrogen-only therapy. Oestrogen-only hormone therapy probably makes little to no difference to coronary events, and probably increases the risk of stroke and gallbladder disease.

Systematic review
Evidence
Relevance

Supporting literature

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.

Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.

+9 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Menopause & Women's Health.

Does hormone replacement therapy increase breast cancer risk?

Combined estrogen-progestin therapy is associated with a small increased breast cancer risk in WHI and observational data. Estrogen-alone in hysterectomized women showed lower risk in WHI, but interpretation depends on regimen, duration, and individual risk factors.

10 linked studies

Does hormone replacement therapy reduce cardiovascular risk in early menopause?

The timing hypothesis suggests earlier initiation may differ from late initiation, where WHI showed harm for combined therapy. Current guidelines emphasize individualized risk assessment rather than routine cardioprotection.

14 linked studies

Does hormone replacement therapy increase venous thromboembolism risk?

Oral estrogen increases venous thromboembolism risk compared with no therapy. Transdermal estrogen appears to carry lower thrombotic risk in observational studies and is often preferred in women at elevated VTE risk.

14 linked studies

Is there a critical timing window for cardiovascular benefit from HRT?

The critical-window concept proposes that starting HRT closer to menopause may yield different cardiovascular effects than starting later. WHI subgroup analyses inform but do not prove this hypothesis for routine practice.

14 linked studies

Go deeper on Menopause & Women's Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Menopause & Women's HealthView pricing